Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension. (Source: CancerNetwork)
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ocCZ1j
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Abstract Helmet manufacturers recommend replacing a bicycle helmet after an impact or after anywhere from 2 to 10 years of use. The goal o...
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Abstract Electro-Fenton (EF), an advanced oxidation process, can be combined with a biological process for efficient treatment of wastewate...
-
ACS Nano DOI: 10.1021/acsnano.6b07082 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2j1vZRU via...
-
ABSTRACT Polygenic scores (PGS) summarize the genetic contribution of a person's genotype to a disease or phenotype. They can be used ...
-
bmj;356/mar29_1/j1571/FAF1faKunal Patel/Hindustani Times/Getty ImagesNearly 40 000 doctors in Delhi and Mumbai have gone on strike to demand...
-
Abstract Background Volasertib, a potent and selective polo-like kinase inhibitor, has shown to increase response rates and improve surv...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου